Veeva CRM Now Integrated with Crossix DIFA Marketing Analytics

Mittwoch, 29.04.20 13:03
Kursticker auf einer digitalen Anzeige.
Bildquelle: pixabay

PLEASANTON, Calif. –

Veeva today announced Veeva CRM Boost for DIFA, which will bring Veeva CRM field activity data into the Crossix DIFA marketing analytics platform starting in Q3 2020. The new offering is free to Crossix DIFA customers with Veeva CRM, giving brands full visibility into customer engagement across channels so they can better assess impact and optimize their efforts across sales and marketing.

Veeva CRM Boost for DIFA allows companies to align personal and non-personal promotions and better understand how they are working together. For example, brands can see the impact of media campaigns on healthcare professionals (HCPs) recently detailed or sampled by the field.

Brands can also link HCP engagement to direct-to-consumer campaigns for a comprehensive view of how sales and marketing influence patient behavior. With this new view, marketers can optimize consumer campaigns to drive patients to field-engaged HCPs.

“In combining with Veeva, we knew we had the potential to change the way life sciences customers plan, execute, and measure their commercial strategies by bringing together sales and marketing,” said Asaf Evenhaim, CEO of Crossix, a Veeva company. “This is the first step in realizing that vision as we give brands a view across campaigns and channels they’ve never had before.”

Crossix DIFA leverages the Crossix Data Platform to link consumer and HCP marketing investments to patient behavior and health outcomes. The Crossix Data Platform is a world-class technology platform built for the development and delivery of large-scale patient data and analytics. The Crossix Platform uses distributed technology and data science to collect, connect, and distribute daily data from disparate sources with privacy, accuracy and agility.

Learn more about Veeva CRM Boost for DIFA at Veeva Commercial & Medical Summit on June 9-10, 2020. Register for the online event and stay up-to-date on program details at Crossix.com/summit.

Additional Information

For more on Veeva CRM Boost for DIFA, visit: veeva.com/CRMBoost
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
Like Veeva on Facebook: facebook.com/veevasystems

About Crossix Solutions, a Veeva Company

A pioneer in patient data, privacy, and analytics, Crossix leverages the industry’s most advanced technology to connect comprehensive health and non-health data, covering more than 300 million lives – all in a privacy-safe way. It delivers data and insights to over 200 brands from top 20 pharma companies as well as leading health systems, pharmacies, and wellness brands. For more information, visit crossix.com.

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 850 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.



Quelle: Business Wire




Heute im Fokus

Bayer: Ist die Aktie jetzt ein Schnäppchen? Bis zu acht neue Mitglieder im SDax erwartet Deutlicher Sprung beim Spritpreis zum Jahreswechsel - keine Entlastung für Autofahrer
Bayer: Ist die Aktie jetzt ein Schnäppchen?
Bayer: Ist die Aktie jetzt ein Schnäppchen?
Die Bayer-Aktie befindet sich aktuell massiv auf Talfahrt und kracht deutlich unter die Kursmarke von 50 Euro. Doch lohnt sich der Einstieg jetzt?...

News und Analysen

Biontech-Aktie und die Alternativen

Biontech-Aktie: Gibt es (bessere) Alternativen? Die Biontech-Aktie kennt derzeit nur einen Weg: Nach oben! Am 30. November 2020 schraubte sich der Titel des Mainzer Biotech-Spezialisten ...weiterlesen

Seite: 1 | 2 | 3 | 4 | 5 | 6 | ... | 15367 ►

Kurssuche

Die beliebtesten Aktien der Deutschen

Die beliebtesten Aktien der Deutschen
Pünktlich zum Tag der Deutschen Einheit hat der Online-Broker Consorsbank die Depots seiner Kunden einem Ost-West-Vergleich unterzogen. Dabei zeigt sich, dass unter Wessis und Ossis eine weitgehende Einigkeit herrscht, wenn es ums Thema Aktienauswahl geht. Denn wie die folgende Tabelle verdeutlicht, variieren die Platzierungen der Top 10 nur um Nuancen.
© 1994-2020 by boerse.de - Quelle für Kurse und Daten: ARIVA.DE AG - boerse.de übernimmt keine Gewähr